Seminars in Fetal & Neonatal Medicine
Volume 11, Issue 3 , Pages 198-206 , June 2006

Neonatal thromboembolic emergencies

  • Courtney Thornburg

      Affiliations

    • Department of Pediatrics, Duke University, Durham, North Carolina, USA
    • ,
  • Steven Pipe

      Affiliations

    • Department of Pediatrics and Communicable Diseases, Hemophilia and Coagulation Disorders Program, University of Michigan, L2110 Women's Hospital, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 734 936 6393; fax: +1 734 936 5953.

References 

  1. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the healthy premature infant. Blood. 1988;72:1651–1657
  2. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost. 1995;74:415–425
  3. Nowak-Gottl U, von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed. 1997;76:F163–F167
  4. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics. 1995;96:939–943
  5. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990;12:95–104
  6. Andrew M, Brooker LA. Blood component therapy in neonatal hemostatic disorders. Transfus Med Rev. 1995;9:231–250
  7. Rajasekhar D, Kestin AS, Bednarek FJ, Ellis PA, Barnard MR, Michelson AD. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thromb Haemost. 1994;72:957–963
  8. Ries M, Klinge J, Rauch R. Age-related reference values for activation markers of the coagulation and fibrinolytic systems in children. Thromb Res. 1997;85:341–344
  9. Ries M, Klinge J, Rauch R, Trusen B, Zenker M, Keuper H, et al. In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults. J Pediatr Hematol Oncol. 1996;18:346–351
  10. Nowak-Gottl U, Kosch A, Schlegel N. Neonatal thromboembolism. Semin Thromb Hemost. 2003;29:227–234
  11. Nowak-Gottl U, Duering C, Kempf-Bielack B, Strater R. Thromboembolic diseases in neonates and children. Pathophysiol Haemost Thromb. 2003;33:269–274
  12. Heller C, Nowak-Gottl U. Maternal thrombophilia and neonatal thrombosis. Best Pract Res Clin Haematol. 2003;16:333–345
  13. Manco-Johnson MJ, Grabowski EF, Hellgreen M, Kemahli AS, Massicotte MP, Muntean W, et al. Laboratory testing for thrombophilia in pediatric patients. On behalf of the Subcommittee for Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis (ISTH). Thromb Haemost. 2002;88:155–156
  14. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:645S–687S
  15. Andrew ME, Monagle P, deVeber G, Chan AK. Thromboembolic disease and antithrombotic therapy in newborns. Hematology [Am Soc Hematol Educ Program]. 2001;358–374
  16. Lynch JK, Hirtz DG, DeVeber G, Nelson KB. Report of the national institute of neurological disorders and stroke workshop on perinatal and childhood stroke. Pediatrics. 2002;109:116–123
  17. deVeber G, Group CPISS . Canadian paediatric ischemic stroke registry: analysis of children with arterial ischemic stroke. Ann Neurol. 2000;48:526a
  18. Golomb MR, MacGregor DL, Domi T, Armstrong DC, McCrindle BW, Mayank S, et al. Presumed pre- or perinatal arterial ischemic stroke: risk factors and outcomes. Ann Neurol. 2001;50:163–168
  19. deVeber G, Monagle P, Chan A, MacGregor D, Curtis R, Lee S, et al. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol. 1998;55:1539–1543
  20. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian registry of venous thromboembolic complications. J Pediatr. 1998;133:770–776
  21. Kuhle S, Massicotte P, Chan A, Mitchell L. A case series of 72 neonates with renal vein thrombosis. Data from the 1-800-NO-CLOTS Registry. Thromb Haemost. 2004;92:729–733
  22. Bromberg WD, Firlit CF. Fibrinolytic therapy for renal vein thrombosis in the child. J Urol. 1990;143:86–88
  23. Greenway A, Massicotte MP, Monagle P. Neonatal thrombosis and its treatment. Blood Rev. 2004;18:75–84
  24. deVeber G, Andrew M, Adams C, Bjornson B, Booth F, Buckley DJ, et al. Cerebral sinovenous thrombosis in children. N Engl J Med. 2001;345:417–423
  25. Chan AK, Deveber G, Monagle P, Brooker LA, Massicotte PM. Venous thrombosis in children. J Thromb Haemost. 2003;1:1443–1455
  26. Berman W, Fripp RR, Yabek SM, Wernly J, Corlew S. Great vein and right atrial thrombosis in critically ill infants and children with central venous lines. Chest. 1991;99:963–967
  27. Ross P, Ehrenkranz R, Kleinman CS, Seashore JH. Thrombus associated with central venous catheters in infants and children. J Pediatr Surg. 1989;24:253–256
  28. Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost. 1990;16:299–309
  29. Dogan Y, Aygun D, Yilmaz Y, Kanra G, Secmeer G, Besbas N, et al. Severe protein S deficiency associated with heterozygous factor V Leiden mutation in a child with purpura fulminans. Pediatr Hematol Oncol. 2003;20:1–5
  30. Pipe SW, Schmaier AH, Nichols WC, Ginsburg D, Bozynski ME, Castle VP. Neonatal purpura fulminans in association with factor V R506Q mutation. J Pediatr. 1996;128:706–709
  31. Gobel U, von Voss H, Jurgens H, Petrich C, Pothmann R, Sprock I, et al. Efficiency of heparin in the treatment of newborn infants with respiratory distress syndrome and disseminated intravascular coagulation. Eur J Pediatr. 1980;133:47–49
  32. Andrew M, Massicotte-Nolan P, Mitchell L, Cassidy K. Dysfunctional antithrombin III in sick premature infants. Pediatr Res. 1985;19:237–239
  33. von Kries R, Stannigel H, Gobel U. Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation. Eur J Pediatr. 1985;144:191–194
  34. Kreuz WD, Schneider W, Nowak-Gottl U. Treatment of consumption coagulopathy with antithrombin concentrate in children with acquired antithrombin deficiency–a feasibility pilot study. Eur J Pediatr. 1999;158(Suppl. 3):S187–S191
  35. Gross SJ, Filston HC, Anderson JC. Controlled study of treatment for disseminated intravascular coagulation in the neonate. J Pediatr. 1982;100:445–448
  36. Risch L, Fischer J, Herklotz R, Huber A. Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes. Intensive Care Med. 2004;30:1615–1624
  37. Male C, Johnston M, Sparling C, Brooker L, Andrew M, Massicotte P. The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood. Clin Lab Med. 1999;19:39–69
  38. Andrew M, Marzinotto V, Massicotte P, Blanchette V, Ginsberg J, Brill-Edwards P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res. 1994;35:78–83
  39. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688–698
  40. Massicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK, et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res. 2003;109:93–99
  41. Streif W, Goebel G, Chan AK, Massicotte MP. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed. 2003;88:F365–F370
  42. Michaels LA, Gurian M, Hegyi T, Drachtman RA. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics. 2004;114:703–707
  43. Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AK, Julian JA, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood. 1999;94:3007–3014
  44. Rijken DC, Otter M, Kuiper J, van Berkel TJ. Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells. Thromb Res Suppl. 1990;10:63–71
  45. Manco-Johnson MJ, Grabowski EF, Hellgreen M, Kemahli AS, Massicotte MP, Muntean W, et al. Recommendations for tPA thrombolysis in children. On behalf of the scientific subcommittee on perinatal and pediatric thrombosis of the scientific and standardization committee of the international society of thrombosis and haemostasis. Thromb Haemost. 2002;88:157–158
  46. Weiner GM, Castle VP, DiPietro MA, Faix RG. Successful treatment of neonatal arterial thromboses with recombinant tissue plasminogen activator. J Pediatr. 1998;133:133–136
  47. Zenz W, Arlt F, Sodia S, Berghold A. Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years. Semin Thromb Hemost. 1997;23:321–332
  48. Balasa VV. New anticoagulants: a pediatric perspective. Pediatr Blood Cancer. 2005;
  49. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3:1843–1853
  50. Young G. Current and future antithrombotic agents in children. Expert Rev Cardiovasc Ther. 2004;2:523–534
  51. Andrew M, Deveber G. Pediatric thromboembolism and stroke protocols. Hamilton: B.C. Decker, Inc.; 1997;

PII: S1744-165X(06)00006-0

doi: 10.1016/j.siny.2006.01.005

Seminars in Fetal & Neonatal Medicine
Volume 11, Issue 3 , Pages 198-206 , June 2006

Article Tools